George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
"Another buying opportunity guys"
not in reality, been trying a very modest top up for last 20 mins, no dice, but of course i am able to sell (at the ask no less) if i wanted too.
reconfirms the only way is up, seen this pattern many times, used to frustrate but now accept it as affirmation i am onto a winner
The document is actually a great read, if i had a US $ account i would buy some!
At the mid price of $5.25 ( offer range $4.25-$6.25) the value of LUCY will be a smidgeon under $50m (and have a cash balance of $13m!) so Innovation eyeware's 55% value (at $5.25 per share) is $27m of which TEK owns 81% so gives TEK a holding worth c$22m. That's my reading at least.
> 2 good RNS' in two days
> this forum's reaction - initially (pre-market), primarily euphoria, follwed by "sack the chairman/ceo" when the share price doesn't rise
> MM's follow this and other forums and react to what they read, and of course they know what to expect
> full disclosure i am a LTH (also in EKF as it happens), and below water, but i added very modestly yesterday at 12.1 and will again if sentiment takes it much further into the 11's as, for me, the RNS' point to a rosier future, but what do i know
> GL Trader - great post, by far the best i've read on here in......probably forever
Young drive online rise for newspapers and magazines
Alex Ralph
Wednesday August 25 2021, 12.01am BST, The Times
Consumers aged 18 to 24 are the most likely to have access to a paid news-site or magazine subscription online
Younger readers buying online subscriptions to newspapers and magazines have helped boost digital publishing sales.
Revenues increased by 31.9 per cent to £152 million in the first quarter of this year, compared with a year ago, according to an index from the Association of Online Publishers (AOP) and Deloitte.
The majority of revenue came from display advertising, rising by 4.7 per cent to £53.6 million. Revenue from subscriptions, though, jumped 48.8 per cent to £33.3 million.
Dan Ison, lead partner for telecommunications, media and entertainment at Deloitte, called the subscription revenue growth “staggering” and a “clear sign that the industry may be building back stronger” after the pandemic’s impact. In the first quarter of 2019 before the pandemic it had risen by 4 per cent.
He said that data from Deloitte’s research into digital consumer trends found that consumers aged 18 to 24 are the most likely to have access to a paid news-site or magazine subscription.
“Galvanising loyalty particularly among this age group should remain a key priority for publishers,” he said.
The AOP represents digital publishing companies, including News UK, publisher of The Times.
The report involved 16 publishers, including business-to-consumer and business-to-business operations.
DHSC outstanding payments and the judicial review process
As at 30 June 2021 Abingdon is owed a total of £6.7m plus interest from the DHSC for components that Abingdon has procured on the DHSC's behalf (£1.5m) and for AbC-19TM kits (£5.2m inc. vat) the Company has delivered to the DHSC in the period November 2020 through to January 2021.
Despite having been informed by the DHSC in January 2021, verbally and in writing, that payment for the 1m tests had been cleared, the Company understands that the DHSC has now chosen not to pay any of these outstanding sums until after the completion of the Judicial Review proceedings (the "JR") initiated by the Good Law Project ("GLP"). The DHSC has also stated that, if Abingdon commences legal proceedings to recover the outstanding sums, it will apply to have those proceedings stayed until after the determination of the JR. The DHSC seeks to avoid its contractual obligations despite having accepted delivery of the products the Company have supplied, and which it is using, and for components purchased on behalf of the DHSC at its request. Abingdon therefore continues to pursue the DHSC for payment.
With regard to the JR, which was initiated by GLP as a challenge to the Secretary of State for Health and Social Care, Abingdon is participating as an "Interested Party". In addition to correcting inaccurate statements made by GLP in the JR, Abingdon wishes to ensure that inaccurate statements do not go unchallenged in the public domain. On 9th August 2021 Abingdon announced that it had made publicly available its Detailed Grounds of Resistance and a letter which was sent to GLP on 4th May 2021 which clarified the facts of the matter. These documents are available to view on the Company's website to highlight to Abingdon shareholders and employees that the Company have been actively seeking to provide clarity and to seek a resolution to these matters and correct a number of factual inaccuracies.
The JR is scheduled to be heard in early December 2021.
The lack of payment has already had significant implications for Abingdon, a Northern Powerhouse company, and its employees and, due to the need to contain costs and manage cash, the Company's workforce has reduced from 190 to 130 employees over the past four months with a number of valued employees having to be made redundant. The pressure on cash flow will increase the longer that payment by DHSC is outstanding. As a small UK company that stepped up to support the UK Government when asked and a Company that has no political affiliations at all it feels that the only people directly affected by the judicial review process are Abingdon's employees, investors and other stakeholders.
"Bid= 19.50
Ask= 21
SP=18.90
Hmm......
I wish they would sort this out. It happens a lot. Is it really 18.90? - cm22"
MM's do this a lot because:
> it depresses the price overnight and encourages sellers because they think they get a good price on opening "higher"
> if there is an rns (or a natural continuation of the rise) in the morning it falsely inflates the percentage rise, which also encourages sellers (eg up 20% rather than actual 10% means more will take profit)
So a UT trade below the spread is a clear sign this is headed up and MMs want to encourage sellers (I see it a lot in popular PI shares that I own, often many days in a row), also the reverse is true with a UT above the spread, although not as common
all we need now is the usual army of (paid?) naysayers and we are guaranteed a good week or three..
Well that was a waste of 20 mins, reading through today's posts..... was hoping to see comments on:
> Skin Trust Club expanding - android app added in Q3 - RoW soon hopefully
> Labskin "rocking" in Gerry's vernacular
> Microtox PD (wow) passed P3 trials spotting covid and other pathogens in real time - in China - in Europe - in USA
> Microtox BT (4 second breath test) latest results due imminently
> China Resources JV (OR BIGGER) & US roll out in Q3
> results this week and more importantly the forward looking statements
Respect Chesh, i don't know how you can be bothered, but fair play, i'd buy you a beer
Dear mr butchers bike,
Intrigued by your suspicions - my account on ADVFN used to be zmar90 (you can probably check) as well but i lost the password. I live in NE Thailand currently, hence the "early morning post" (not everyone lives in the uk), you will not find my post on any other website unless someone else copies it. I thought it was a reasoned post myself, compared to a lot i try and avoid reading on both sites, definitely expressing the positives for sure, that's why I'm here after all. My name is Mark (zmar was an old bp handle when i worked there) and i have a youtube account where i talk about all my 20 shares (ncyt biggest holding) and a twitter account, happy to share details of both if you want further verification i am not a fake account .
Cheers
Mark
The NCYT share price is held back largely because it is a PI favourite which, in turn, causes it to become a trader’s stock. It has also become a news driven stock, and, because there is not an overabundance of news, it can be held in a range for long periods. The world and it’s husband knows it is undervalued and consequently hoard’s of PI’s/traders have bought in, the latter at least expecting to take a profit on any rise (10% most likely).
With all the negativity / uncertainty around the DHSC dispute it is easy/ier for MMs to keep the price in this low range ensuring traders can’t take that profit, so they get frustrated, cash up and therefore help the MM’s maintain their strategy.
But they can’t hold it forever, and when they have built up their supply of shares and, on any good news, they will let it rise fast (or won’t be able to hold it) and will profitably sell down their supply into the rising market (as seen after the last R&D update which went from c3.8 – 5.7 over a few sessions). When this happens, and the buying/selling frenzy takes a pause, they will drop the price again and attempt to stabilize at a lower range to rinse and repeat the process. We have seen it many times before with NCYT (stagnation in an “undervalued” range) and I suspect we will see it again.
Keep the faith, a rise from this stagnant range (3.30-3.55) is inevitable, and I strongly suspect that 3.30 is as low as it will go because of the buying pressure in the 40’s/30’s is too great (I am one of many topping-up and poised to add more on each dip) and when that news drops the dam will burst, and we know there WILL be news by end of June so not long to wait it out
No Opinion
RE: Exciting times aheadThu 18:16
GJB just tweet great presentation''
AND WASN'T IT JUST, worth getting to the end just to hear Glenn's answers to last couple of questions, "significant growth (prospects)" significantly under valued (SP)" "convinced we will knock it out of the park" comments left me buzzing, also clearly stated there was "a stuffed pipeline (new products)" that will hope to be updating on soon.
Glenn could soon be vying with Gerry for CEO of the year, so much to love about the prospects of both MSYS and DVRG
After comparable reactions to most on here I decided that i continued to have faith in Graham, and that he does what is best for the Company and not what is best for shareholders, in the sure and certain knowledge that we (the shareholders that hang in there) will reap the benefits of his Company focus.
I topped up in 4 of my 6 trading accounts on Friday and if per chance it drops further next week i will do so again. Why? Well basically given the current cash balance and the non-DHSC Q1 income (plus probable delayed DHSC income at some point) i can't see the current market cap being justified let alone dropping further.
It is not as much fun being invested here now for sure, but ever the optimist I believe it will be again, just not sure when, but heyho, onwards and more specifically...upwards!
It appears that TEK did not put up any of the Belluscura fund raise as they have 7.71m value before and after the raise (perhaps understandable if looking to exit at some point). Whereas, Nigel Wray seems to have put up 1m and director David Poutney 100k - which bodes well for future prospects in the after market
from May 10th so maybe already posted - but worth a repeat i thought
https://www.globenewswire.com/news-release/2021/05/11/2226791/0/en/Attogene-to-expand-SARS-CoV-2-variants-testing-in-the-United-States.html
Attogene to expand SARS-CoV-2 variants testing in the United States
Attogene, a biotechnology firm in Austin, TX is announcing expansion of its product line to address the rapidly evolving testing demands within the United States, these efforts can have significant public health impact particularly as SARS-CoV-2 continues to mutate around the world.
Austin, United States , May 10, 2021 (GLOBE NEWSWIRE) -- Attogene, a biotechnology company based in Austin, Texas, is expanding its product line to address the rapidly evolving SARS-CoV-2 testing demands within the United States. These efforts will have a significant public health impact as new SARS-CoV-2 variants continue to be discovered around the world.
Specifically, Attogene will add to its current portfolio of PrimerDesign reagents (Novacyt Group), eight new RUO assays, which arguably may be the most complete variant detection portfolio currently available worldwide to address the globally prevalent variants of SARS-CoV-2. The company is striving to meet all arising COVID-19 challenges as quickly as possible and will also make available an assay to detect the novel variants originally identified in India. For more info on the variant tests available visit https://attogene.com/shop/snpsig-variplex-covid-19
Collectively, these efforts reinforce Attogene’s commitment to leadership in responding to the urgent market requirements and public health needs in the U.S.
Lance P. Ford, PhD, President and CEO of Attogene Corporation said: “We are pleased to be able to provide Novacyt’s state of the art assays to ensure that the country has cutting edge detection tests to better monitor SARS-CoV-2 variants. We look forward to the opportunity of expanding our support of variant testing in the U.S. through our established infrastructure.”
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialization, contract design and manufacturing.
Novacyt’s lead business units are comprised of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, hematology, and serology markets as do its global partners, which include major corporations. For more information visit https://novacyt.com
Attogene is a biotechnology company named after the unit prefix in the metric system representing (10 negative18th power) that offers cutting edge products and services to address global health concerns. Attogene additionally offers technology to address the growing threat from cyanotoxins associated by harmful algae blooms and environmental toxins. For more information, v
same on advfn GGGT - love the way they keep exceeding already updated expectations, and seems like the contract extension will justify continued optimism
Merci, for providing last/latest (time will tell) sub 7 squid top up (694 for me). It's a tad disconcerting to be averaging down, i must confess, but it's only a matter of time, and patience, before reality bites and our predictive hindsight tells us we should have added more in the bargain basement sale.
I hadn't appreciated this (final para of RNS) presumably TEK will increase it's holding beneficially!
From previous investments made by Tekcapital in Belluscura, Tekcapital holds warrants to purchase 1,273,078 shares at 13p and 600,000 shares at 15p. Additionally, concomitant with Belluscura's receipt of FDA Clearance, Tekcapital has 30 days to exercise an option to purchase up to approximately 4.8m Belluscura shares between 21p - 23p depending upon amount invested. If all warrants and options are exercised, than Tekcapital would hold approximately 17.1m shares in Belluscura.